Hikma and Vectura sign global agreement to develop generic versions of GSK's Ellipta portfolio

Hikma Pharmaceuticals signed an agreement with Vectura Group for the global development and commercialization of generic versions of GSK's Ellipta portfolio, using Vectura's Open-Inhale-Close dry powder inhaler device. Hikma made an upfront payment of $15 million.

“This agreement leverages the investment we have made and the experience we have gained through our generic Advair Diskus programme.”hikma.com

• 1 source
• hikma.comHikma announces global agreement with Vectura to develop generic versions of GSK’s Ellipta® portfolio | HikmaNov 8, 2018

Summarized from public sources; check the original articles before acting on it.